453 related articles for article (PubMed ID: 26544950)
21. Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model.
Lin YW; Zhou Q; Onufrak NJ; Wirth V; Chen K; Wang J; Forrest A; Chan HK; Li J
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559256
[TBL] [Abstract][Full Text] [Related]
22. Changes in strategies for optimal antibacterial therapy in cystic fibrosis.
Ratjen F
Int J Antimicrob Agents; 2001 Feb; 17(2):93-6. PubMed ID: 11165111
[TBL] [Abstract][Full Text] [Related]
23. Rhesus θ-defensin-1 (RTD-1) exhibits in vitro and in vivo activity against cystic fibrosis strains of Pseudomonas aeruginosa.
Beringer PM; Bensman TJ; Ho H; Agnello M; Denovel N; Nguyen A; Wong-Beringer A; She R; Tran DQ; Moskowitz SM; Selsted ME
J Antimicrob Chemother; 2016 Jan; 71(1):181-8. PubMed ID: 26433781
[TBL] [Abstract][Full Text] [Related]
24. Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response.
Lam JC; Somayaji R; Surette MG; Rabin HR; Parkins MD
BMC Infect Dis; 2015 Mar; 15():145. PubMed ID: 25887462
[TBL] [Abstract][Full Text] [Related]
25. Bacterial sinusitis can be a focus for initial lung colonisation and chronic lung infection in patients with cystic fibrosis.
Aanæs K
J Cyst Fibros; 2013 Sep; 12 Suppl 2():S1-20. PubMed ID: 24064077
[TBL] [Abstract][Full Text] [Related]
26. Changes in the lung bacteriome in relation to antipseudomonal therapy in children with cystic fibrosis.
Kramná L; Dřevínek P; Lin J; Kulich M; Cinek O
Folia Microbiol (Praha); 2018 Mar; 63(2):237-248. PubMed ID: 29127619
[TBL] [Abstract][Full Text] [Related]
27. In vivo efficacy of doripenem (DRPM) against Pseudomonas aeruginosa in murine chronic respiratory tract infection model.
Araki N; Yanagihara K; Morinaga Y; Yamada K; Yamada Y; Kohno S; Kamihira S
J Infect Chemother; 2011 Jun; 17(3):318-21. PubMed ID: 20972597
[TBL] [Abstract][Full Text] [Related]
28. Oral Azithromycin Use and the Recovery of Lung Function from Pulmonary Exacerbations Treated with Intravenous Tobramycin or Colistimethate in Adults with Cystic Fibrosis.
Somayaji R; Russell R; Cogen JD; Goss CH; Nick SE; Saavedra MT; Taylor-Cousar JL; Nick JA; Nichols DP
Ann Am Thorac Soc; 2019 Jul; 16(7):853-860. PubMed ID: 30840835
[No Abstract] [Full Text] [Related]
29. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Greally P; Whitaker P; Peckham D
Curr Med Res Opin; 2012 Jun; 28(6):1059-67. PubMed ID: 22401602
[TBL] [Abstract][Full Text] [Related]
30. The effects of inhaled aztreonam on the cystic fibrosis lung microbiome.
Heirali AA; Workentine ML; Acosta N; Poonja A; Storey DG; Somayaji R; Rabin HR; Whelan FJ; Surette MG; Parkins MD
Microbiome; 2017 May; 5(1):51. PubMed ID: 28476135
[TBL] [Abstract][Full Text] [Related]
31. Antibacterial efficacy of inhaled squalamine in a rat model of chronic Pseudomonas aeruginosa pneumonia.
Hraiech S; Brégeon F; Brunel JM; Rolain JM; Lepidi H; Andrieu V; Raoult D; Papazian L; Roch A
J Antimicrob Chemother; 2012 Oct; 67(10):2452-8. PubMed ID: 22744759
[TBL] [Abstract][Full Text] [Related]
32. Aerosol treatment with MNEI suppresses bacterial proliferation in a model of chronic Pseudomonas aeruginosa lung infection.
Woods DE; Cantin A; Cooley J; Kenney DM; Remold-O'Donnell E
Pediatr Pulmonol; 2005 Feb; 39(2):141-9. PubMed ID: 15633200
[TBL] [Abstract][Full Text] [Related]
33. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
Cantón R; Cobos N; de Gracia J; Baquero F; Honorato J; Gartner S; Alvarez A; Salcedo A; Oliver A; García-Quetglas E;
Clin Microbiol Infect; 2005 Sep; 11(9):690-703. PubMed ID: 16104983
[TBL] [Abstract][Full Text] [Related]
34. Microbiota in Exhaled Breath Condensate and the Lung.
Glendinning L; Wright S; Tennant P; Gill AC; Collie D; McLachlan G
Appl Environ Microbiol; 2017 Jun; 83(12):. PubMed ID: 28389539
[TBL] [Abstract][Full Text] [Related]
35. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection.
Milla CE; Chmiel JF; Accurso FJ; VanDevanter DR; Konstan MW; Yarranton G; Geller DE;
Pediatr Pulmonol; 2014 Jul; 49(7):650-8. PubMed ID: 24019259
[TBL] [Abstract][Full Text] [Related]
36. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Parkins MD; Elborn JS
Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231
[TBL] [Abstract][Full Text] [Related]
37. Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and Pseudomonas aeruginosa.
Klepac-Ceraj V; Lemon KP; Martin TR; Allgaier M; Kembel SW; Knapp AA; Lory S; Brodie EL; Lynch SV; Bohannan BJ; Green JL; Maurer BA; Kolter R
Environ Microbiol; 2010 May; 12(5):1293-303. PubMed ID: 20192960
[TBL] [Abstract][Full Text] [Related]
38. Effects of combined treatment with ambroxol and ciprofloxacin on catheter-associated Pseudomonas aeruginosa biofilms in a rat model.
Lu Q; Yu J; Bao L; Ran T; Zhong H
Chemotherapy; 2013; 59(1):51-6. PubMed ID: 23816803
[TBL] [Abstract][Full Text] [Related]
39. Managing Pseudomonas aeruginosa respiratory infections in cystic fibrosis.
Langan KM; Kotsimbos T; Peleg AY
Curr Opin Infect Dis; 2015 Dec; 28(6):547-56. PubMed ID: 26524327
[TBL] [Abstract][Full Text] [Related]
40. Roflumilast Increases Bacterial Load and Dissemination in a Model of Pseudomononas Aeruginosa Airway Infection.
Kasetty G; Papareddy P; Bhongir RK; Egesten A
J Pharmacol Exp Ther; 2016 Apr; 357(1):66-72. PubMed ID: 26865680
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
